公开(公告)号：WO2010120861A1

公开(公告)日：2010-10-21

申请号：PCT/US2010/031005

申请日：2010-04-14

Applicant: ENZON PHARMACEUTICALS, INC. ,  SANTARIS PHARMA A/S ,  ZHANG, Yixian ,  QU, Zhengxing ,  GREENBERGER, Lee Martin

Inventor： ZHANG, Yixian ,  QU, Zhengxing ,  GREENBERGER, Lee Martin

IPC: A61K31/70 ,  C07H21/04

CPC classification number: C07D487/04 ,  C07D519/00 ,  C12N15/1137 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3231 ,  C12N2310/3341 ,  C12N2310/341

Abstract: One aspect of the invention provides methods for treating cancers which are resistant to treatment with a protein tyrosine kinase inhibitor by co-treatment with the protein tyrosine kinase inhibitor and one or more antisense oligomers that reduce the expression of HER3 and/or HER2 and/or EGFR. Another aspect of the invention provides methods for treating cancers by co-treatment with an inhibitor of HER2 and one or more antisense oligomers that reduce the expression of HER3.

Abstract translation: 本发明的一个方面提供了通过与蛋白酪氨酸激酶抑制剂和一种或多种降低HER3和/或HER2和/或HER2的表达的反义寡聚体共同治疗来治疗对蛋白质酪氨酸激酶抑制剂有抗性的癌症的方法 EGFR。 本发明的另一方面提供了通过与HER2抑制剂和一种或多种降低HER3表达的反义寡聚体共同治疗来治疗癌症的方法。

公开(公告)号：WO2007015848B1

公开(公告)日：2007-11-15

申请号：PCT/US2006027820

申请日：2006-07-14

Applicant: IMMUNOMEDICS INC ,  NORDSTROM DIANE ,  GOLDENBERG DAVID M ,  QU ZHENGXING ,  CHANG CHIEN HSING ,  ROSSI EDWARD A ,  YANG JENG-DAR

Inventor： GOLDENBERG DAVID M ,  QU ZHENGXING ,  CHANG CHIEN HSING ,  ROSSI EDWARD A ,  YANG JENG-DAR

IPC: C12N5/00 ,  C12N5/09 ,  C12N15/00

CPC classification number: C07K16/00 ,  A61K2039/505 ,  C07K14/4747 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/3007 ,  C07K2317/24 ,  C07K2317/31 ,  C12N5/0694 ,  C12N2500/90 ,  C12N2501/48 ,  C12N2510/02 ,  C12P21/02

Abstract: Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.

公开(公告)号：WO2006094192A2

公开(公告)日：2006-09-08

申请号：PCT/US2006/007598

申请日：2006-03-03

Applicant: IMMUNOMEDICS, INC. ,  GOLDENBERG, David, M. ,  HANSEN, Hans, J. ,  QU, Zhengxing ,  CHANG, Chen-Hsing

Inventor： GOLDENBERG, David, M. ,  HANSEN, Hans, J. ,  QU, Zhengxing ,  CHANG, Chen-Hsing

CPC classification number: C07K16/2833 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6849 ,  A61K47/6867 ,  A61K51/1027 ,  A61K51/1093 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/28 ,  C07K16/2887 ,  C07K16/4241 ,  C07K19/00 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/92

Abstract: Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapuetic and diagnostic, as well as research-related uses for such antibodies, are provided.

Abstract translation: 提供特异性结合HLA-DR的人源化抗体。 抗体识别由鼠单克隆抗体L243识别的表位。 提供了制备此类抗体的方法，含有此类抗体的药物组合物，以及临床治疗和诊断以及用于此类抗体的研究相关用途。

公开(公告)号：WO2005012493A3

公开(公告)日：2005-02-10

申请号：PCT/US2004/024636

申请日：2004-08-02

Applicant: IMMUNOMEDICS, INC. ,  HANSEN, Hans J. ,  QU, Zhengxing ,  GOLDENBERG, David M.

Inventor： HANSEN, Hans J. ,  QU, Zhengxing ,  GOLDENBERG, David M.

IPC: A61K39/395

Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases.

公开(公告)号：WO2004013180A2

公开(公告)日：2004-02-12

申请号：PCT/GB0303325

申请日：2003-08-01

Applicant: IMMUNOMEDICS INC ,  MCCALL JOHN DOUGLAS ,  HANSEN HANS ,  QU ZHENGXING ,  GOLDENBERG DAVID M

Inventor： HANSEN HANS ,  QU ZHENGXING ,  GOLDENBERG DAVID M

IPC: A61K41/00 ,  A61K47/48 ,  A61K49/00 ,  A61K51/10 ,  A61P35/00 ,  C07K16/18 ,  C07K16/30 ,  C12N15/13 ,  G01N33/574 ,  G01N33/68 ,  A61K39/395 ,  C07K16/46 ,  C12N5/10 ,  C12N15/62 ,  C12N15/79 ,  C12Q1/68 ,  G01N33/573

CPC classification number: C07K16/30 ,  A61K41/0095 ,  A61K47/6843 ,  A61K49/0002 ,  A61K51/1018 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/3076 ,  C07K2317/24 ,  C07K2317/56 ,  G01N33/57484 ,  G01N33/689

Abstract: The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.

Abstract translation: 本发明提供了人源化，嵌合和人抗甲胎蛋白抗体，融合蛋白及其片段。 抗体，融合蛋白及其片段以及与其他合适抗体的组合可用于治疗和诊断肝细胞癌，肝母细胞瘤，生殖细胞肿瘤癌和其他AFP产生性肿瘤。

公开(公告)号：WO2007015691A9

公开(公告)日：2007-04-19

申请号：PCT/US2005026224

申请日：2005-07-25

Applicant: IMMUNOMEDICS INC ,  GOLDENBERG DAVID M ,  QU ZHENGXING ,  HORAK EVA ,  HORAK IVAN D ,  CHANG CHIEN-HSING KEN ,  ROSSI EDMUND A ,  YANG JENG-DAR

Inventor： GOLDENBERG DAVID M ,  QU ZHENGXING ,  HORAK EVA ,  HORAK IVAN D ,  CHANG CHIEN-HSING KEN ,  ROSSI EDMUND A ,  YANG JENG-DAR

IPC: C07H21/04 ,  C07K14/475 ,  C07K14/505 ,  C07K14/52 ,  C07K14/54 ,  C07K14/56 ,  C07K16/18 ,  C12N9/00 ,  C12P21/06

CPC classification number: C12P21/02 ,  C07K14/4747 ,  C07K16/00

Abstract: Disclosed herein are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. By transfecting cells in culture with an apoptosis-inhibiting gene or vector, cells in culture can survive longer, resulting in extension of the state and yield of protein biosynthesis. Expression of the apoptosis-inhibitor within the cells, because it does not kill the cells, allows the cells, or an increased fraction thereof, to be maintained in culture for longer periods. This invention then allows for controlled, enhanced protein production of cell lines for commercial and research uses, particularly the enhanced production of growth factors, interferons, interleukins, hormones, enzymes, and monoclonal antibodies, and the like. The method preferentially involves eukaryotic cells in culture, and more advantageously mammalian cells in culture.

Abstract translation: 本文公开了用于增加细胞培养物的寿命并允许增加蛋白质，优选重组蛋白质如抗体，肽，酶，生长因子，白细胞介素，干扰素，激素和疫苗的产生的组合物和方法。 通过用凋亡抑制基因或载体转染培养细胞，培养的细胞可以存活更长时间，导致蛋白质生物合成的状态和产量的延长。 凋亡抑制因子在细胞内的表达，因为它不杀死细胞，所以允许细胞或其增加的级分在培养物中保持更长时间。 然后，本发明允许用于商业和研究用途的细胞系的受控，增强的蛋白质生产，特别是增强的生长因子，干扰素，白细胞介素，激素，酶和单克隆抗体等的生产。 该方法优选涉及培养中的真核细胞，并且更优选培养中的哺乳动物细胞。

公开(公告)号：WO2007015691A3

公开(公告)日：2007-02-08

申请号：PCT/US2005/026224

申请日：2005-07-25

Applicant: IMMUNOMEDICS, INC. ,  GOLDENBERG, David M. ,  QU, Zhengxing ,  HORAK, Eva ,  HORAK, Ivan D. ,  CHANG, Chien-hsing Ken ,  ROSSI, Edmund A. ,  YANG, Jeng-dar

Inventor： GOLDENBERG, David M. ,  QU, Zhengxing ,  HORAK, Eva ,  HORAK, Ivan D. ,  CHANG, Chien-hsing Ken ,  ROSSI, Edmund A. ,  YANG, Jeng-dar

IPC: C12P21/06 ,  C12P21/04 ,  C12N5/00

Abstract: Disclosed herein are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. By transfecting cells in culture with an apoptosis-inhibiting gene or vector, cells in culture can survive longer, resulting in extension of the state and yield of protein biosynthesis. Expression of the apoptosis-inhibitor within the cells, because it does not kill the cells, allows the cells, or an increased fraction thereof, to be maintained in culture for longer periods. This invention then allows for controlled, enhanced protein production of cell lines for commercial and research uses, particularly the enhanced production of growth factors, interferons, interleukins, hormones, enzymes, and monoclonal antibodies, and the like. The method preferentially involves eukaryotic cells in culture, and more advantageously mammalian cells in culture.

公开(公告)号：WO2005004809A3

公开(公告)日：2006-02-02

申请号：PCT/US2004020995

申请日：2004-07-01

Applicant: IMMUNOMEDICS INC ,  HANSEN HANS J ,  MCBRIDE WILLIAM J ,  QU ZHENGXING

Inventor： HANSEN HANS J ,  MCBRIDE WILLIAM J ,  QU ZHENGXING

IPC: A61K20060101 ,  A61K39/395 ,  A61K47/48 ,  A61K51/08 ,  A61K51/10 ,  C07K16/28 ,  C07K16/30 ,  C07K16/44 ,  C12N9/00 ,  C07K16/00

CPC classification number: C07K16/2887 ,  A61K47/6897 ,  A61K51/1027 ,  A61K51/1048 ,  A61K51/109 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/3007 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/01

Abstract: Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods.

Abstract translation: 本文提供作为双特异性抗体的多价载体的可靶向构建体，即可靶向构建体的每个分子可以用作两种或更多种双特异性抗体的载体。 还提供了通过可靶向构建体与两种或更多种双特异性抗体缔合形成的可靶向复合物。 将本发明的可靶向构建体和可靶向复合物掺入生物传感器，试剂盒和药物组合物中，并且以多种治疗和其它方法使用。

公开(公告)号：WO2003106495A2

公开(公告)日：2003-12-24

申请号：PCT/GB2003/002593

申请日：2003-06-16

Applicant: IMMUNOMEDICS, INC. ,  MCCALL, John, Douglas ,  GOLDENBERG, David, M. ,  HANSEN, Hans ,  QU, Zhengxing

Inventor： GOLDENBERG, David, M. ,  HANSEN, Hans ,  QU, Zhengxing

IPC: C07K16/00

CPC classification number: A61K49/0008 ,  A61K47/68 ,  A61K51/1057 ,  A61K2039/505 ,  C07K14/4748 ,  C07K16/2896 ,  C07K2317/24

Abstract: This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or more binding sites where these binding sites have affinity towards different epitopes on a target antigen or different target antigens, or have affinity towards a target antigen and a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional antibodies in a host. More specifically, the present invention relates to the tumor-associated antibody designated PAM4. The invention further relates to humanized and human PAM4 antibodies, and the use of such antibodies in diagnosis and therapy.

Abstract translation: 本发明涉及单价和多价单特异性抗体和多价多特异性抗体。 这些抗体的一个实施方案具有一个或多个相同的结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些抗体的另一个实施方案具有两个或多个结合位点，其中这些结合位点对靶抗原或不同靶抗原上的不同表位具有亲和力，或对靶抗原和半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性抗体的重组载体。 更具体地，本发明涉及称为PAM4的肿瘤相关抗体。 本发明还涉及人源化和人类PAM4抗体，以及这些抗体在诊断和治疗中的用途。

公开(公告)号：WO02082041A3

公开(公告)日：2003-09-12

申请号：PCT/US0210235

申请日：2002-04-03

Applicant: IMMUNOMEDICS INC ,  HANSEN HANS J ,  GRIFFITHS GARY L ,  LEUNG SHUI-ON ,  MCBRIDE WILLIAM J ,  QU ZHENGXING ,  GOLDENBERG DAVID M

Inventor： HANSEN HANS J ,  GRIFFITHS GARY L ,  LEUNG SHUI-ON ,  MCBRIDE WILLIAM J ,  QU ZHENGXING ,  GOLDENBERG DAVID M

IPC: G01R33/28 ,  A61B5/055 ,  A61K39/395 ,  A61K49/00 ,  A61K51/00 ,  A61K51/08 ,  A61K51/10 ,  C07K5/107 ,  C07K5/11 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/44 ,  C07K16/46 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12P21/08 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/574 ,  G01N33/577 ,  C07K16/00

CPC classification number: C07K16/468 ,  A61K47/6863 ,  A61K47/6899 ,  A61K51/1048 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/44 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2319/00

Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.

Abstract translation: 本发明涉及一种双特异性抗体或抗体片段，其具有至少一个对靶组织有反应性的臂，以及至少一个对接头部分具有反应性的其它臂。 接头部分包括已经制备抗体的半抗原。 抗原性接头与一种或多种治疗剂或诊断剂或酶缀合。 本发明提供用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。